ClinicalTrials.gg
Not yet recruitingNCT07827768AREVIAUpdated Oct 21, 2026

AV-1959R Vaccine in Individuals With Preclinical Alzheimer's Disease

A Phase 2 interventional study of AV-1959R and Placebo in Preclinical Alzheimer's Disease and Alzheimer Disease, sponsored by Institute for Molecular Medicine. Not yet recruiting. Open to participants aged 55 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Institute for Molecular Medicine · Phase 2, Interventional, and Prevention

How we know

Updated Oct 21, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
55 Years to 80 Years
Sex
All
01

Study summary

This Phase 2 study will evaluate the safety, tolerability, immunogenicity, and amyloid-lowering effect of AV-1959R in cognitively unimpaired adults with preclinical Alzheimer's disease. Approximately 160 participants will be randomized to receive AV-1959R or placebo and will be followed for 78 weeks. The study will assess safety, immune responses, brain amyloid, and Alzheimer's disease-related biomarkers.

Read the detailed description

This Phase 2 study is designed to further evaluate AV-1959R in cognitively unimpaired individuals with preclinical Alzheimer's disease, with emphasis on safety, tolerability, immunogenicity, and surrogate efficacy based on changes in Alzheimer's disease-related biomarkers and amyloid pathology

02

Conditions studied

  • Preclinical Alzheimer's Disease
  • Alzheimer Disease

Browse trials for

Keywords

  • AV-1959R
  • Amyloid-beta
  • Alzheimer's Vaccine
  • Secondary Prevention of Alzheimer's Disease
  • Alzheimer's Disease Prevention
  • Active Immunotherapy for Alzheimer's Disease
03

In context

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

This study's planned enrollment of 160 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.

Browse Alzheimer Disease studies →

Lead sponsor

Institute for Molecular Medicine is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
55 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male or female participants 55 to 80 years of age, inclusive, at screening. Signed before initiation of study-related procedures.

Cognitively unimpaired participants with preclinical Alzheimer's disease meeting all of the following:

CDR global score = 0 at screening. score ≥26 at screening, with education adjustment. WMS-R LM2 score ≥ 6 Plasma p-tau217/Aβ1-42 ratio ≥0.00738. Brain amyloid burden ≥ 20CL. Vision and hearing sufficient to comply with study procedures, in the investigator's judgment.

Stable concomitant medications for management of existing medical conditions, as appropriate.

Women must be of non- as defined in the protocol. Men must meet protocol-defined and sperm donation requirements. Ability, in the investigator's opinion, to understand the study and comply with study requirements.

Exclusion criteria

Exclusion Criteria:

Screening MRI showing abnormalities, including protocol-defined infarcts, excessive microbleeds, hemosiderosis, superficial siderosis, or ARIA-E.

to MRI. Serious illness requiring systemic treatment and/or hospitalization within 4 weeks before study entry.

Clinically relevant cardiovascular, respiratory, gastrointestinal, endocrine, immunologic, hematologic, neurologic, or other systemic disease that could interfere with participation or follow-up.

Insulin-dependent diabetes. Clinically significant abnormalities, including protocol-defined conduction abnormalities or abnormalities.

Pre-existing disease. History of seizure disorder, except protocol-permitted use of certain antiepileptic medications for chronic pain.

Any medical, psychological, or social condition that may interfere with participation, compliance, or safety.

Participation in another drug study or use of an investigational drug within 30 days or 5 half-lives, whichever is longer, before dosing.

Prior amyloid-beta or tau immunotherapy, including vaccine or monoclonal antibody, within 1 year before screening.

Recent use of protocol-defined immunomodulatory or growth-stimulating agents. Chronic use of protocol-defined anticoagulants or antiplatelet agents; aspirin is permitted.

Parenteral use of immunoglobulin preparations, blood products, or plasma derivatives.

History of severe local or systemic vaccine reactions or significant allergic reactions.

Clinically significant laboratory abnormalities at screening. Positive testing for -1/2, surface antigen, or virus.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    AV-1959R

    Participants will receive AV-1959R 100 micrograms with adjuvant by intramuscular injection at Weeks 0, 4, and 44.

    Biological: AV-1959R

  • Placebo comparator
    Placebo

    Participants will receive placebo with adjuvant by intramuscular injection at Weeks 0, 4, and 44.

    Drug: Placebo

Interventions

  • BiologicalAV-1959R

    Investigational amyloid-beta vaccine, AV-1959R, 100 micrograms, administered intramuscularly with adjuvant at Weeks 0, 4, and 44.

  • DrugPlacebo

    Placebo administered by intramuscular injection with adjuvant at Weeks 0, 4, and 44.

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs)

    Number and percentage of participants with treatment-emergent adverse events.

    Time frame: From first study intervention through Week 78

  2. Incidence of ARIA-E and ARIA-H

    Number and percentage of participants with MRI-detected amyloid-related imaging abnormalities, including ARIA-E and ARIA-H.

    Time frame: Through Week 78

  3. Clinically Significant Changes in Safety Assessments

    Number and percentage of participants with clinically significant changes in vital signs, ECG, laboratory assessments, physical examinations, or neurological examinations.

    Time frame: Through Week 78

  4. Change From Baseline in Columbia-Suicide Severity Rating Scale Suicidal Ideation Severity Score

    Change from baseline in the Columbia-Suicide Severity Rating Scale (C-SSRS) suicidal ideation severity score, comparing AV-1959R and placebo groups. The score ranges from 0 to 5, with higher scores indicating greater severity of suicidal ideation.

    Time frame: Baseline and Weeks 4, 44, and 78

  5. Serum Anti-Amyloid-Beta Antibody Levels

    Serum anti-amyloid-beta antibody levels following vaccination, comparing AV-1959R and placebo groups.

    Time frame: Baseline through Week 78

Secondary outcomes

  1. T-cell responses to MultiTEP and amyloid-beta

    Assessment of MultiTEP-specific T-cell responses and autoreactive anti-amyloid-beta T-cell responses, comparing AV-1959R and placebo groups.

    Time frame: Baseline through Week 78

  2. Change From Baseline in Global Brain Amyloid Burden

    Change from baseline in global brain amyloid burden measured by amyloid PET using the Centiloid scale, comparing the AV-1959R and placebo groups.

    Time frame: Baseline to Week 78

  3. Change From Baseline in Plasma p-tau217/Aβ1-42 Ratio

    Change from baseline in plasma Lumipulse p-tau217/Aβ1-42 ratio, comparing the AV-1959R and placebo groups.

    Time frame: Baseline through Week 78

Other outcomes

  1. Change From Baseline in Clinical Dementia Rating-Sum of Boxes Score

    Change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score, comparing AV-1959R and placebo groups. The total score ranges from 0 to 18, with higher scores indicating greater cognitive and functional impairment.

    Time frame: Baseline to Week 78

  2. Change From Baseline in Plasma Amyloid Biomarkers

    Change from baseline in plasma Aβ42, Aβ40, and Aβ42/Aβ40 ratio, comparing the AV-1959R and placebo groups.

    Time frame: Baseline through Week 78

  3. Change From Baseline in Plasma Tau Biomarker Concentrations

    Change from baseline in plasma concentrations of BD-tau, MTBR-tau243, total tau, p-tau181, p-tau231, and p-tau217.

    Time frame: Baseline through Week 78

  4. Change From Baseline in Plasma Neurofilament Light Chain Concentration

    Change from baseline in plasma neurofilament light chain (NfL) concentration.

    Time frame: Baseline through Week 78

  5. Change From Baseline in Plasma Glial Fibrillary Acidic Protein Concentration

    Change from baseline in plasma glial fibrillary acidic protein (GFAP) concentration.

    Time frame: Baseline through Week 78

  6. Change From Baseline in Brain Tau Burden

    Change from baseline in pathological tau accumulation measured by quantitative tau PET imaging, comparing the AV-1959R and placebo groups.

    Time frame: Baseline to Week 78

  7. Changes in T-Cell and B-Cell Receptor Repertoires and Lineages

    Exploratory analysis of changes in T-cell receptor and B-cell receptor repertoires and T-cell and B-cell lineages in response to vaccination.

    Time frame: Baseline through Week 78

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Individual participant data are not planned to be shared.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2027; primary completion for Oct 2029, 24 months later.

Of 128 non-industry phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 69. This study's planned 24 months is below that.

Counting every sponsor, half of 259 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: start Mar 2027 → Oct 2027, primary completion Jun 2029 → Oct 2029 and completion Jun 2029 → Nov 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2026
First posted
Sep 18, 2026
StartEst.
Oct 1, 2027was Mar 2027
Primary completionEst.
Oct 15, 2029was Jun 2029
CompletionEst.
Nov 15, 2029was Jun 2029
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Mar 1, 2027→Oct 1, 2027
Oct 21, 2026
Primary completion
Jun 15, 2029→Oct 15, 2029
Oct 21, 2026
Study completion
Jun 15, 2029→Nov 15, 2029
Oct 21, 2026
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedCDR global score = 0 at screening. MMSE score ≥26 at screening, with education adjustment. WMS-R LM2 score ≥ 6 Plasma p-tau217/Aβ1-42 ratio ≥0.00738. Brain amyloid burden ≥ 20CL. Vision and hearing sufficient to comply with study procedures, in the investigator's judgment.
Oct 13, 2026
Show all 2 updates
  1. Oct 21, 2026
    Start date Mar 1, 2027→Oct 1, 2027
    Primary completion Jun 15, 2029→Oct 15, 2029
    Study completion Jun 15, 2029→Nov 15, 2029
    + 1 other change: identifiers
  2. Oct 13, 2026
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedCDR global score = 0 at screening. MMSE score ≥26 at screening, with education adjustment. WMS-R LM2 score ≥ 6 Plasma p-tau217/Aβ1-42 ratio ≥0.00738. Brain amyloid burden ≥ 20CL. Vision and hearing sufficient to comply with study procedures, in the investigator's judgment.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07827768
Lead sponsor
Institute for Molecular Medicine
Collaborators
Nuravax, Inc.
Responsible party
Sponsor
First posted
Sep 18, 2026
Start date
Oct 1, 2027 (estimated)
Primary completion
Oct 15, 2029 (estimated)
Completion
Nov 15, 2029 (estimated)
Last update
Oct 21, 2026

Study contacts

Roman Kniazev
Contact
rkniazev@immed.org
7145963981
Michael Agadjanyan
principal investigator · Institute for Molecular Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion